USFDA advisors back Eli Lilly’s Alzheimer’s drug ahead of its expected approval
Eli Lilly‘s Alzheimer’s drug has won the backing of federal health advisers. This can play a crucial role in the treatment’s expected approval for people with mild dementia caused by Alzheimer’s disease. According to a report by the news agency Associated …